What is Akoya Biosciences Inc share price today?

Akoya Biosciences Inc (AKYA) share price today is {{live_price}}.

Can Indians buy Akoya Biosciences Inc shares?

Yes, Indians can invest in the Akoya Biosciences Inc (AKYA) from India. With INDmoney, you can buy Akoya Biosciences Inc at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Akoya Biosciences Inc at zero transaction cost.

How can I buy Akoya Biosciences Inc shares from India?

It is very easy to buy Akoya Biosciences Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Akoya Biosciences Inc be purchased?

Yes, you can buy fractional shares of Akoya Biosciences Inc with INDmoney app.

What are the documents required to start investing in Akoya Biosciences Inc stocks?

To start investing in Akoya Biosciences Inc, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Akoya Biosciences Inc

Today’s highest price of Akoya Biosciences Inc (AKYA) is {{1_rba_end}}. Today’s lowest price of Akoya Biosciences Inc (AKYA) is {{1_rba_st}}.

What is today's market capitalisation of Akoya Biosciences Inc

Today's market capitalisation of Akoya Biosciences Inc AKYA is 116.8M

What is the 52 Week High and Low Range of Akoya Biosciences Inc

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Akoya Biosciences Inc is down from its 52 Week High?

Akoya Biosciences Inc (AKYA) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Akoya Biosciences Inc is up from its 52 Week low?

Akoya Biosciences Inc (AKYA) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Akoya Biosciences Inc?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Akoya Biosciences Inc

Mr. Brian McKelligon is the current Chief Executive Officer (CEO) of Akoya Biosciences Inc.

Home>
US Stocks>
Akoya Biosciences Inc

Akoya Biosciences Inc (AKYA)

$2.36

-0.02

(-0.84%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

$2.34
$2.41
$2.36
0.85%
Downside
Day's Volatility :2.9%
Upside
2.07%
$1.88
$6.31
$2.36
20.34%
Downside
52 Weeks Volatility :70.21%
Upside
62.6%

Returns

Period	Akoya Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	15.12%	5.1%	0.0%
6 Months	-50.42%	4.9%	0.0%
1 Year	-48.02%	16.6%	0.0%
3 Years	-83.59%	13.2%	-22.3%

Highlights

Market Capitalization	116.8M
Book Value	$0.45
Earnings Per Share (EPS)	-1.17
Wall Street Target Price	5.0

Profit Margin	-64.74%
Operating Margin TTM	-47.47%

Return On Assets TTM	-18.09%
Return On Equity TTM	-128.2%

Revenue TTM	93.2M
Revenue Per Share TTM	1.89
Quarterly Revenue Growth YOY	-1.5%
Gross Profit TTM	43.4M
EBITDA	-39.5M
Diluted Eps TTM	-1.17
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	-1.02
EPS Estimate Next Year	-0.54
EPS Estimate Current Quarter	-0.27
EPS Estimate Next Quarter	-0.19

Analyst Recommendation

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Akoya Biosciences Inc(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 111.86%

Current $2.36

Target $5.00

Company Financials

	FY19	Y/Y Change
Revenue	42.2M	-
Net Income	-14.8M	-
Net Profit Margin	-34.93%	-

	FY20	Y/Y Change
Revenue	42.4M	↑ 0.49%
Net Income	-16.7M	↑ 13.25%
Net Profit Margin	-39.36%	↓ 4.43%

	FY21	Y/Y Change
Revenue	54.9M	↑ 29.39%
Net Income	-42.9M	↑ 157.0%
Net Profit Margin	-78.18%	↓ 38.82%

	FY22	Y/Y Change
Revenue	74.9M	↑ 36.31%
Net Income	-70.6M	↑ 64.53%
Net Profit Margin	-94.37%	↓ 16.19%

	FY23	Y/Y Change
Revenue	96.6M	↑ 29.09%
Net Income	-63.3M	↓ 10.36%
Net Profit Margin	-65.53%	↑ 28.84%

	Q1 FY23	Q/Q Change
Revenue	21.4M	↑ 0.9%
Net Income	-18.8M	↓ 0.39%
Net Profit Margin	-87.82%	↑ 1.13%

	Q2 FY23	Q/Q Change
Revenue	23.5M	↑ 9.86%
Net Income	-20.8M	↑ 10.64%
Net Profit Margin	-88.44%	↓ 0.62%

	Q3 FY23	Q/Q Change
Revenue	25.2M	↑ 7.2%
Net Income	-12.9M	↓ 37.91%
Net Profit Margin	-51.22%	↑ 37.22%

	Q4 FY23	Q/Q Change
Revenue	26.5M	↑ 5.04%
Net Income	-10.8M	↓ 16.37%
Net Profit Margin	-40.78%	↑ 10.44%

	Q1 FY24	Q/Q Change
Revenue	18.4M	↓ 30.72%
Net Income	-23.5M	↑ 117.4%
Net Profit Margin	-127.98%	↓ 87.2%

	Q2 FY24	Q/Q Change
Revenue	23.2M	↑ 26.23%
Net Income	-13.1M	↓ 44.01%
Net Profit Margin	-56.76%	↑ 71.22%

	FY19	Y/Y Change
Total Assets	89.4M	-
Total Liabilities	119.6M	-

	FY20	Y/Y Change
Total Assets	77.7M	↓ 13.14%
Total Liabilities	59.1M	↓ 50.58%

	FY21	Y/Y Change
Total Assets	190.9M	↑ 145.82%
Total Liabilities	69.6M	↑ 17.71%

	FY22	Y/Y Change
Total Assets	176.0M	↓ 7.79%
Total Liabilities	117.5M	↑ 68.86%

	FY23	Y/Y Change
Total Assets	180.4M	↑ 2.46%
Total Liabilities	126.6M	↑ 7.79%

	Q1 FY23	Q/Q Change
Total Assets	154.3M	↓ 12.35%
Total Liabilities	112.2M	↓ 4.49%

	Q2 FY23	Q/Q Change
Total Assets	188.9M	↑ 22.41%
Total Liabilities	117.0M	↑ 4.28%

	Q3 FY23	Q/Q Change
Total Assets	177.2M	↓ 6.16%
Total Liabilities	115.3M	↓ 1.46%

	Q4 FY23	Q/Q Change
Total Assets	180.4M	↑ 1.76%
Total Liabilities	126.6M	↑ 9.83%

	Q1 FY24	Q/Q Change
Total Assets	154.8M	↓ 14.2%
Total Liabilities	122.0M	↓ 3.61%

	Q2 FY24	Q/Q Change
Total Assets	143.7M	↓ 7.11%
Total Liabilities	121.5M	↓ 0.44%

	FY19	Y/Y Change
Operating Cash Flow	-13.8M	-
Investing Cash Flow	-12.9M	-
Financing Cash Flow	28.6M	-

	FY20	Y/Y Change
Operating Cash Flow	-6.8M	↓ 50.33%
Investing Cash Flow	6.7M	↓ 152.19%
Financing Cash Flow	5.5M	↓ 80.79%

	FY21	Y/Y Change
Operating Cash Flow	-36.1M	↑ 427.08%
Investing Cash Flow	-5.1M	↓ 175.71%
Financing Cash Flow	137.0M	↑ 2397.9%

	FY22	Y/Y Change
Operating Cash Flow	-53.5M	↑ 48.32%
Investing Cash Flow	-14.1M	↑ 176.38%
Financing Cash Flow	28.7M	↓ 79.04%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-19.8M	↑ 97.44%
Investing Cash Flow	6.2M	↓ 72.0%
Financing Cash Flow	-419.0K	↓ 104.08%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-11.8M	↓ 40.26%
Investing Cash Flow	-1.4M	↓ 122.97%
Financing Cash Flow	46.3M	↓ 11156.56%

Technicals Summary

Sell

Neutral

Buy

Akoya Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Akoya Biosciences Inc	20.41%	-50.42%	-48.02%	-83.59%	-90.94%
Intuitive Surgical, Inc.	5.02%	20.15%	58.74%	31.28%	184.98%
Resmed Inc.	16.09%	27.14%	62.7%	-17.28%	81.24%
Becton, Dickinson And Company	0.02%	-2.08%	-12.88%	-9.76%	-9.75%
West Pharmaceutical Services Inc	1.18%	-17.93%	-26.4%	-35.64%	104.36%
Alcon Ag	3.83%	8.9%	15.02%	11.44%	61.54%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Akoya Biosciences Inc	NA	NA	NA	-1.02	-1.28	-0.18	NA	0.45
Intuitive Surgical, Inc.	81.91	81.91	4.06	6.65	0.16	0.08	NA	41.4
Resmed Inc.	35.33	35.33	2.05	7.71	0.23	0.13	0.01	33.11
Becton, Dickinson And Company	46.72	46.72	1.08	13.11	0.06	0.03	0.02	89.5
West Pharmaceutical Services Inc	42.71	42.71	5.15	6.51	0.2	0.11	0.0	35.49
Alcon Ag	42.64	42.64	3.53	3.05	0.05	0.03	0.0	42.35

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Akoya Biosciences Inc	Buy	$116.8M	-90.94%	NA	-64.74%
Intuitive Surgical, Inc.	Buy	$169.4B	184.98%	81.91	27.65%
Resmed Inc.	Buy	$36.0B	81.24%	35.33	21.79%
Becton, Dickinson And Company	Buy	$67.4B	-9.75%	46.72	7.13%
West Pharmaceutical Services Inc	Buy	$21.8B	104.36%	42.71	18.25%
Alcon Ag	Buy	$46.7B	61.54%	42.64	11.44%

Insights on Akoya Biosciences Inc

Increasing Revenue
Revenue is up for the last 2 quarters, 18.35M → 23.16M (in $), with an average increase of 20.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -23.48M → -13.14M (in $), with an average increase of 78.6% per quarter
Vs RMD
In the last 1 year, Resmed Inc. has given 62.7% return, outperforming this stock by 110.7%
Vs ISRG
In the last 3 years, Akoya Biosciences Inc has experienced a drawdown of -83.6%, however Intuitive Surgical, Inc. resisted the overall trend and outperformed by 66.3%